vTv Therapeutics Inc. (VTVT) Stock Rating Reaffirmed by Piper Jaffray Cos.
vTv Therapeutics Inc. (NASDAQ:VTVT)‘s stock had its “overweight” rating reaffirmed by analysts at Piper Jaffray Cos. in a report released on Saturday. They currently have a $24.00 target price on the stock. Piper Jaffray Cos.’s target price indicates a potential upside of 243.35% from the stock’s previous close.
Other research analysts have also recently issued reports about the company. HC Wainwright initiated coverage on vTv Therapeutics in a research report on Monday, September 26th. They set a “buy” rating and a $13.00 price target for the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 price objective on shares of vTv Therapeutics in a research report on Friday, August 19th. Finally, Zacks Investment Research raised vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 26th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. vTv Therapeutics has an average rating of “Buy” and a consensus price target of $16.00.
Shares of vTv Therapeutics (NASDAQ:VTVT) traded up 5.27% during mid-day trading on Friday, reaching $6.99. The company had a trading volume of 19,107 shares. The firm’s 50 day moving average is $6.57 and its 200-day moving average is $5.94. vTv Therapeutics has a 12-month low of $4.84 and a 12-month high of $8.22. The stock’s market capitalization is $67.73 million.
vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Tuesday, August 16th. The company reported ($0.47) EPS for the quarter. On average, analysts expect that vTv Therapeutics will post ($1.61) earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in VTVT. Kennedy Capital Management Inc. purchased a new position in shares of vTv Therapeutics during the first quarter worth $282,000. BlackRock Fund Advisors raised its position in shares of vTv Therapeutics by 26.6% in the second quarter. BlackRock Fund Advisors now owns 202,202 shares of the company’s stock worth $1,173,000 after buying an additional 42,520 shares during the period. Ameriprise Financial Inc. raised its position in shares of vTv Therapeutics by 17.2% in the second quarter. Ameriprise Financial Inc. now owns 161,484 shares of the company’s stock worth $936,000 after buying an additional 23,705 shares during the period. State Street Corp raised its position in shares of vTv Therapeutics by 37.5% in the second quarter. State Street Corp now owns 84,222 shares of the company’s stock worth $488,000 after buying an additional 22,983 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of vTv Therapeutics by 23.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 96,439 shares of the company’s stock worth $559,000 after buying an additional 18,112 shares during the period. 12.84% of the stock is owned by institutional investors.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.